Centre for Heart, Lung and Vascular Health, School of Health and Exercise Sciences, University of British Columbia Okanagan, Kelowna, BC.
Cardiff School of Sport and Health Sciences, Cardiff Metropolitan University, Cardiff.
Chest. 2022 Apr;161(4):1022-1035. doi: 10.1016/j.chest.2021.08.075. Epub 2021 Sep 8.
Increasing iron bioavailability attenuates hypoxic pulmonary vasoconstriction in both lowlanders and Sherpas at high altitude. In contrast, the pulmonary vasculature of Andean individuals with chronic mountain sickness (CMS) is resistant to iron administration. Although pulmonary vascular remodeling and hypertension are characteristic features of CMS, the effect of iron administration in healthy Andean individuals, to our knowledge, has not been investigated. If the interplay between iron status and pulmonary vascular tone in healthy Andean individuals remains intact, this could provide valuable clinical insight into the role of iron regulation at high altitude.
Is the pulmonary vasculature in healthy Andean individuals responsive to iron infusion?
In a double-blinded, block-randomized design, 24 healthy high-altitude Andean individuals and 22 partially acclimatized lowlanders at 4,300 m (Cerro de Pasco, Peru) received an IV infusion of either 200 mg of iron (III)-hydroxide sucrose or saline. Markers of iron status were collected at baseline and 4 h after infusion. Echocardiography was performed in participants during room air breathing (partial pressure of inspired oxygen [Pio] of approximately 96 mm Hg) and during exaggerated hypoxia (Pio of approximately 73 mm Hg) at baseline and at 2 and 4 h after the infusion.
Iron infusion reduced pulmonary artery systolic pressure (PASP) by approximately 2.5 mm Hg in room air (main effect, P < .001) and by approximately 7 mm Hg during exaggerated hypoxia (main effect, P < .001) in both lowlanders and healthy Andean highlanders. There was no change in PASP after the infusion of saline. Iron metrics were comparable between groups, except for serum ferritin, which was 1.8-fold higher at baseline in the Andean individuals than in the lowlanders (95% CI, 74-121 ng/mL vs 37-70 ng/mL, respectively; P = .003).
The pulmonary vasculature of healthy Andean individuals and lowlanders remains sensitive to iron infusion, and this response seems to differ from the pathologic characteristics of CMS.
增加铁的生物利用度可减轻低地居民和高海拔夏尔巴人缺氧性肺血管收缩。相比之下,慢性高原病(CMS)的安第斯人肺部血管对铁剂治疗有抵抗力。尽管肺部血管重塑和高血压是 CMS 的特征性表现,但我们所知,健康安第斯人中铁剂的作用尚未得到研究。如果健康安第斯人体内铁状态和肺血管张力之间的相互作用仍然存在,这可能为高海拔地区铁调节的作用提供有价值的临床见解。
健康安第斯人肺部血管对铁输注有反应吗?
在一项双盲、随机分组设计中,24 名健康的高海拔安第斯人(秘鲁塞罗德帕斯科)和 22 名部分适应的低地居民(海拔 4300 米)接受 200mg 三价羟蔗糖铁或生理盐水的静脉输注。在输注前和输注后 4 小时采集铁状态标志物。在参与者进行房间空气呼吸(吸入氧分压[PIO]约为 96mmHg)和输注后 2 和 4 小时进行过度缺氧(PIO 约为 73mmHg)时进行超声心动图检查。
铁输注使低地居民和健康安第斯高海拔居民在房间空气(主要作用,P <.001)和过度缺氧(主要作用,P <.001)时的肺动脉收缩压(PASP)分别降低约 2.5mmHg 和 7mmHg。输注生理盐水后 PASP 无变化。两组的铁指标相似,除了血清铁蛋白,安第斯人基线时比低地居民高 1.8 倍(95%CI,74-121ng/mL 比 37-70ng/mL;P =.003)。
健康安第斯人和低地居民的肺部血管对铁输注仍然敏感,这种反应似乎与 CMS 的病理特征不同。